We report our experience of non-tuberculous mycobacterial infection associated with the tunnel of Hickman-Broviac central venous catheters in immunosuppressed patients with haematological malignancies undergoing high-dose chemotherapy supported by BMT. The problem is rare and difficult to treat. Our cases are unique in developing tunnel site mycobacterial infection well after the tunnelled catheters were removed. We diagnosed one case of Mycobacterium chelonae, which is a well-documented cause of such infections, and two cases of Mycobacterium haemophilum, which are the first reported cases in this setting. Early wide surgical excision of the infected tunnel site and prolonged antibiotic therapy is necessary. Despite these measures recurrence occurred in two cases. Close liaison with the microbiology laboratory is needed to ensure the appropriate culture media and conditions are used for these fastidious organisms. Empiric antibiotic regimens should be based on the likely organism. Drugs active against M. chelonae and M. haemophilum should be included. Keywords: mycobacteria; central venous catheter; Hickman line; infection; M. chelonae; M. haemophilum Tunnelled venous access devices are used commonly in bone marrow transplantation to allow long-term venous access. These lines are associated with infectious and thrombotic complications. Mycobacterial infections are rarely encountered. Tunnel-related infection is even less frequently reported. We discuss the problem, outline our experience and review the literature.
Case reports

Case 1
A 28-year-old woman with AML achieved complete remission with the first course of standard induction chemotherapy. Prolonged aplasia for several months complicated the first consolidation therapy. One year after diagnosis an abscess developed adjacent to the site of the previously removed Groshong catheter, with persistently negative microbiological cultures ( Figure 1 ).
Fifteen months after initial diagnosis the AML relapsed. She went on to allogeneic bone marrow transplantation (1992) using busulphan and cyclophosphamide conditioning with short-course methotrexate and cyclosporin graftversus-host disease (GVHD) prophylaxis. Grade II/III cutaneous, hepatic and gastrointestinal GVHD was treated with prednisolone 25 mg daily and Psoralen Ultra Violet A (PUVA) therapy.
Three months later the left chest wall lesion had deteriorated and numerous granulomata and acid-fast bacilli, later identified as Mycobacterium chelonae (abscessus), was isolated at biopsy. Wide surgical excision was undertaken. The lesion penetrated to within 0.5 cm of the pectoralis major muscle and was extensive, necessitating subtotal mastectomy. Anti-mycobacterial therapy was i.v. amikacin 500 mg once daily and i.v. cefoxitin 2 g four times a day.
A few months later M. chelonae recurred, just above the scar, with 2-3 cm of induration. Local excision and imipenem were used initially and later amikacin and clarithromycin (1 g twice a day). The area remained ulcerated for months, but was slowly healing. Intensive immunosuppression was continued because of progressive GVHD including obliterative bronchiolitis.
One year later a further lesion developed which was indurated, red and tender; the old lesion ulcerated. Amikacin and cefoxitin were employed as the organism had become resistant to clarithromycin. Deafness was noted, probably due to cumulative toxicity of amikacin; although amikacin levels were never toxic. Death occurred 3 years after initial presentation from respiratory failure (obliterative bronchiolitis), disseminated mycobacterial sepsis (blood cultures positive for M. chelonae) and chronic GVHD. 
Case 2
A 29-year-old woman was diagnosed with intermediategrade non-Hodgkin's lymphoma (diffuse mixed small and large cell) at 26 weeks gestation. Skin, lung, liver and spleen were involved. The baby was delivered early, and CEOP chemotherapy was commenced, without improvement. A salvage regimen containing dexamethasone, highdose cytarabine and carboplatin was used, followed by double autologous peripheral blood stem cell transplantation at 3 and 5 months after diagnosis (1998). Interleukin-2 and interferon-alpha were then employed. Three months after the second autograft an inflamed mass developed in the right supraclavicular region with some inflammation at the CVC site. Cellulitis with lymphadenopathy were suspected and flucloxacillin commenced. The lesion became harder and less inflamed but did not disappear. Fine needle aspiration (FNA) cytology failed to demonstrate recurrent lymphoma or any microbial organism. Only neutrophils were seen. Since the lesions failed to respond, antibiotics were changed to ciprofloxacin and cephalexin. The lesion slowly deteriorated, and new ulcerated lesions developed along the track of the previous catheter. Further FNA was perfomed which demonstrated acid-fast bacilli. Wide surgical excision of the catheter track and two adjacent lymph nodes confirmed granulomata with multi-nucleate giant cells. One of the nodes contained a few acid-fast bacilli. Culture confirmed Mycobacterium haemophilum after 7 weeks incubation. Therapy consisted of amikacin, clarithromycin, ciprofloxacin and meropenem for 3 weeks, then amikacin and meropenem were ceased and ethambutol started. She continues on this regimen with a healed wound and no sign of recurrence. Immunosuppressive or immunomodulating therapy has been withheld indefinitely.
Case 3
A 26-year-old woman with a past history of epilepsy was diagnosed with blastic transformation of CML and received two cycles of idarubicin, high-dose cytarabine and etoposide chemotherapy. Matched unrelated BMT was performed 5 months after diagnosis (1998) using total body irradiation and cyclophosphamide conditioning followed by short-course methotrexate, Campath 1G, steroid and cyclosporin GVHD prophylaxis.
Three months after transplant the site of a previous Hickman catheter (removed after only a few hours because of accidental dislodgement) became ulcerated and infected, associated with a purulent discharge. Flucloxacillin was prescribed but swabs demonstrated leucocytes with no microbial growth. The ulcer persisted and cultures from swabs grew abundant Proteus and Pseudomonas, which were treated with ciprofloxacin. Numerous rapid-growing mycobacteria were also detected after 5 days. Wide surgical excision was performed down to 2 cm from the muscle. Oral clarithromycin 500 mg twice a day, i.v. amikacin 500 mg daily and i.v. meropenem 500 mg three times a day (subsequently changed to i.v. cefoxitin 2 g twice a day) were commenced. The immunosuppression was reduced. Identification of Mycobacterium haemophilum took 7 weeks. Figure 2 demonstrates numerous mycobacteria in the biopsy specimen. CRB = catheter-related bacteraemia; Ab = antibiotic therapy; amik = amikacin; clar = clarithromycin; cotrim = co-trimoxazole (sulphamethoxazole/trimethoprim); cefox = cefoxitin; rif = rifampicin; tic/clav = ticarcillin/clavulanic acid; tob = tobramycin; imip = imipenem; mero = meropenem; etham = ethambutol; cipro = ciprofloxacin.
Two months later the ulcer reappeared and a few AFB were isolated. Repeat surgical excision (to the pectoralis muscle including a cuff of muscle) was undertaken. The drugs were changed to oral rifampicin 600 mg daily, ciprofloxacin 750 mg twice a day and clarithromycin 500 mg twice a day. Cyclosporin and prednisolone doses were reduced further. Even though amikacin levels were never toxic, unfortunately deafness and vertigo developed after 8 weeks. Currently the skin is intact and therapy continues. 3-5 The infections are mainly due to gram-negative bacilli and gram-positive cocci, with some caused by fungi. 6 Mycobacterial infections related to catheters have been rarely reported ( Table 1 ). The largest study of mycobacterial infection following BMT, from the University of Minnesota, 7 reports only 11 cases of mycobacterial infection of any site in 2241 BMT recipients over a 20-year period. In total only six patients had Mycobacteria (all M. chelonae or M. fortuitum) from blood culture or CVC tunnel. Only three presented with CVC tunnel inflammation. All seemed to respond well to CVC removal and 1-6 months of antimicrobial therapy. Surgery was not mentioned. Fifteen cases of catheter-related Mycobacterium fortuitum complex (fortuitum/chelonae) have been diagnosed at the MD Anderson Cancer Center. 8 Successful treatment relied upon catheter removal and antibiotics. They also noted, as we have, that tunnel infection required surgical excision. Flynn et al 9 also found that in three patients the local infection relapsed after the catheter was removed and the patients had received parenteral therapy for Ͼ3 weeks. Infection only resolved after surgical excision of the infected tunnel. 9 M. neoaurum infection of a Hickman catheter was reported in an allogeneic BMT recipient with recovery following line removal and antimicrobial therapy. 10 More recently a case of M. aurum related to a catheter resolved only after antibiotics and subsequent catheter removal. 11 A case of M. smegmatis catheter-related bacteraemia in a cancer patient also responded to line removal and antibiotics. 12 Only one episode of mycobacterial sepsis was noted in the large study of 1630 tunnelled venous access catheters in 1431 cancer patients at the Memorial SloanKettering Cancer Center 3 due to M. chelonei, although no details were given. Two cases of non-tuberculous Mycobacterial catheter-related sepsis 13 and two cases of Mycobacterium avium complex bacteraemia 14 have been reported in children with cancer.
Discussion
Our cases illustrate the clinical problem of non-tuberculous mycobacterial infections of the catheter tunnel site. The problem is thankfully rare in the BMT setting: three cases since 1983 during which time we have transplanted 401 people (0.75% mycobacterial infection rate). The rate of all catheter-related mycobacterial infection at Minnesota is 0.27%. 7 There is little written in the literature regarding tunnel-related infection. The major problem is that these mycobacteria are ubiquitous environmental organisms and infections occur in heavily immunosuppressed patients who are recovering from BMT, with reduced cell-mediated immunity, and often with concomitant GVHD. Therefore reduction of immunosuppressive therapy, although desirable, is often not an option. Immunosuppression, particularly loss of cell-mediated immunity and neutropenia are the most important risk factors. Haematological malignancy also seems to be more common than nonhaematological malignancy. Foreign bodies and materials (such as catheters) also increase the risk for these infections. 8, 9 The therapy has toxicity, mainly attributable to the aminoglycosides. Two of our cases developed vestibulocochlear damage. This problem seems to occur after some time (cumulative dose), and does not have to be associated with toxic levels. Amikacin is thought to preferentially affect auditory function rather than vestibular function, 15 although one of our cases developed both, and never had toxic levels with frequent assays. The onset can be abrupt. Regular monitoring of function by audiometry would be prudent as the damage may be reversible if therapy is ceased before symptoms develop.
Mycobacteria are notoriously fastidious, and identification can take up to 2 months, with a longer delay for antibiotic sensitivity testing. The diagnosis needs to be suspected and cultures set-up on appropriate media. Empiric antibiotic cover, based on likely organisms, should be initiated until the organism is later identified. PCR techniques are now used to assist and speed the identification of standard Mycobacterium tuberculosis, but primers are not available for the atypical mycobacteria. There is no 'standard' therapy for these organisms as they are rare, and display varying sensitivity to antibiotics. Current regimens used include combinations of drugs most likely to be active. According to Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases 4th edition, 16 ,17 therapy for the rapid growers (M. chelonae and M. fortuitum) should include surgical excision of all involved tissue. Antibiotics recommended for M. fortuitum are amikacin, cefoxitin, ciprofloxacin and sulphonamides and for M. chelonae amikacin, doxycycline, erythromycin, imipenem, and clarithromycin although M. chelonae tends to be more resistant to drug therapy. M. haemophilum has a much more limited clinical database (with less than 100 reported cases). Responses to surgery, modification of immune suppression, and antibiotics such as rifampicin, doxycycline and cotrimoxazole have been reported.
Our experience of tunnelled catheters in BMT patients is that these infections, in contrast to other reported series, occurred in relation to the tunnelled catheter site well after the line had been removed. Additionally wide surgical excision was required, and our patients had ongoing infection with documented recurrence despite antimicrobial therapy and prompt wide surgical excision. We find these infections to be a difficult clinical problem causing significant morbidity. M. chelonae has been documented as causing these infections, but this is the first report of M. haemophilum in this setting. M. haemophilum is becoming an increasingly recognised cause of infection in the immunosuppressed. It predominantly causes cutaneous lesions, grows best in cooler environments, and is difficult to culture even on appropriate media. 18, 19 It has also been implicated in bacteraemia, osteomyelitis, septic arthritis, pneumonitis in the immunosuppressed, and lymphadenitis in otherwise healthy children. 20, 21 The only other report of M. haemophilum in BMT recipients is from the Memorial Sloan-Kettering Cancer Center. Three patients presented with the classical cutaneous lesions and survived, and two others developed isolated pulmonary disease and died. 22 M. haemophilum should be added to the list of possible causative organisms, and the choice of empiric antibiotic therapy should take this into account.
